

Original Research

Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA

Yongcheng Jiang^{1,†}, Lina Guo^{2,†}, Houde He³, Haonan Chen⁴, Tao Chen⁵, Yan Liu^{5,*}, Wang Zhao^{1,*}

¹Neurology Department, The People's Hospital of Chizhou, 247100 Chizhou, Anhui, China

²Clinical Nutrition Department, Guangdong Provincial Hospital of Chinese Medicine, 510030 Guangzhou, Guangdong, China

³School of Public Health, Southern Medical University, 528305 Guangzhou, Guangdong, China

⁴The First Clinical Medical School, Guangdong Pharmaceutical University, 510006 Guangzhou, Guangdong, China

⁵Research and Development Center, Center of Human Microecology Engineering and Technology of Guangdong Province, 510700 Guangzhou, Guangdong, China

*Correspondence: liuy598@mail2.sysu.edu.cn (Yan Liu); chizhouwangzhao@163.com (Wang Zhao)

†These authors contributed equally.

Academic Editor: Antoni Camins

Submitted: 8 April 2025 Revised: 5 June 2025 Accepted: 11 June 2025 Published: 26 June 2025

Abstract

Background: Insomnia, the most prevalent sleep disorder, is clinically defined as difficulty initiating or maintaining sleep. Although many medications are effective for insomnia treatment, they carry risks of drug dependence and abuse. The microbiota-gut-brain axis (MGBA) facilitates bidirectional signaling between the gastrointestinal tract and the central nervous system via gut microbes. Probiotics that provide mental and behavioral benefits through MGBA (psychobiotics) offer broad therapeutic potential. **Methods:** A non-toxic, drug-resistant strain of *Lactobacillus reuteri* E9 was isolated and characterized. Its effects were evaluated in a pentylenetetrazol (PTZ)-induced zebrafish model of sleep disorder. Neurotransmitter levels (glycine, serine, taurine, γ -aminobutyric acid (GABA)) and gene expression of GABA/melatonin receptors were analyzed. **Results:** E9 significantly upregulated inhibitory neurotransmitters, including GABA, taurine, glycine, and serine ($p < 0.05$). In PTZ-induced zebrafish, E9 exerted sedative effects by reducing seizures and hyperactivity. Concurrently, E9 upregulated the expression of GABA receptor genes and melatonin receptor (*Mtnr1a*) genes in zebrafish neural tissue. **Conclusions:** *Lactobacillus reuteri* E9 demonstrates potential as a psychobiotic for sleep disorder management by modulating key inhibitory neurotransmitters and sleep-related receptor expression via the MGBA pathway, offering a non-pharmacological alternative to conventional treatments.

Keywords: *Lactobacillus reuteri*; gamma-aminobutyric acid; sleep disorders; zebrafish

1. Introduction

Insomnia, particularly sleep-onset and sleep-maintenance subtypes, ranks among the most prevalent sleep disorders. Sleep deficiency can lead to symptoms including amnesia, irritability, depression, attention deficits, and fatigue. Beyond impairing cognitive function, sleep disorders are associated with metabolic syndromes such as obesity, inflammation, diabetes, and cardiovascular disease [1]. Although multiple pharmacological treatments exist, including benzodiazepine receptor agonists, antihistamines, melatonin receptor agonists, anxiolytics, antidepressants, and antipsychotics, these agents carry significant disadvantages. Notably, they pose risks of dependence, abuse, and adverse effects such as vertigo, headache, somnolence, amnesia, cognitive impairment, and even increased mortality [2]. Consequently, a safe therapeutic alternative is needed to reduce reliance on sedative-hypnotics, thereby improving sleep quality and efficiency in insomnia patients without substantial side effects.

Gut microbiota (GM) influences host physiology through diverse pathways, including nutritional modulation, immune regulation, and neurotransmitter and hormone production. Studies indicate that sleep disorders may contribute to metabolic dysregulation, particularly through aberrant neurotransmitter release and subtle GM alterations [3]. The microbiome-gut-brain axis (MGBA) represents a bidirectional communication network between the gastrointestinal tract and central nervous system, mediated by GM through mechanisms such as immune activation and vagal nerve signaling. Consequently, balanced GM composition may improve sleep via MGBA modulation [4].

Probiotics, defined as live microorganisms conferring health benefits when adequately dosed, have been shown to enhance sleep quality under stress and ameliorate sleep-related memory dysfunction and cognitive impairment [5–8]. Supplementation with γ -aminobutyric acid (GABA)-producing *Lactobacillus* strains significantly increases intestinal *Lactobacillus* abundance and serum GABA levels, attenuating stress responses induced by sleep disruption and



GM dysbiosis [9]. Nevertheless, the underlying neuroendocrine mechanisms remain unclear.

This study investigated the therapeutic mechanism of *Lactobacillus reuteri* E9 (E9) for insomnia using a zebrafish model. E9 was selected based on its documented role in neurotransmitter metabolism. Our findings demonstrate that E9 upregulates neurotransmitters including glycine, serine, taurine, and GABA. Furthermore, E9 exerted sedative effects in pentylenetetrazol (PTZ)-induced insomnia by reducing seizure activity and upregulating GABA receptor and melatonin receptor (Mtnrlaa) gene expression in zebrafish.

2. Materials and Methods

2.1 *Lactobacillus reuteri* E9 Strain Characterization

Optimal Growth Assessment: To establish the optimal incubation parameters for *Lactobacillus reuteri* E9 (deposited at the China General Microbiological Culture Collection Center under accession number CGMCC No. 21768), the strain was cultured aerobically at 37 °C for 48 hours. Colony morphology on agar plates was then evaluated using the streak plate technique. This analysis documented key characteristics of individual colonies, including shape, dimensions, surface texture, margin appearance, opacity, pigmentation, and other morphological traits.

Origin and Molecular Identification: The E9 isolate originated from traditional fermented vegetables (pickles) sourced in Anhui Province, China. Following repeated purification (involving more than three sequential single-colony isolation streaks), the purified culture was subjected to 16S rDNA sequencing for species-level identification. Amplification employed universal primers 27F (5'-AGAGTTTGATCCTGGCTCAG-3') and 1492R (5'-GGTTACCTTGTTACGACTT-3'). Sanger sequencing services were provided by Sangon Biotech (Shanghai, China). The resulting 16S rDNA amplicon sequence was subsequently aligned against the GenBank nucleotide database utilizing the BLAST algorithm (Basic Local Alignment Search Tool).

2.2 Biochemical Characterization

The API 50CHL system (BioMérieux, Lyons, France) employs a standardized panel comprising 49 microtubes containing fermentable carbohydrates, designed for identifying *Lactobacillus* and related bacteria [10]. Each well was inoculated with a standardized suspension of the test organism. During incubation, acid production from metabolized carbohydrates lowers the pH, triggering a chromogenic shift in the pH indicator. This acidification profile constitutes the strain's biochemical fingerprint, used for identification or typing.

Result Interpretation: Test strips were evaluated after 24 and 48 hours of incubation. A color change to yellow in any well indicates substrate acidification, recorded as a positive reaction (+), as the phenol red indicator turns yel-

low at acidic pH. Similarly, a transition from red to black in the esculin control well (tube 25) signifies a positive control reaction. Wells showing no color change were recorded as negative (-).

Biochemical profiles were subsequently analyzed using the Apiweb™ software (Google LLC, Mountain View, CA, USA). This platform queries the reference database, generating identification results that include the species designation. Identification confidence is reflected by two parameters: the % ID value (higher percentages indicate closer matches) and the T-index (values approaching 1.0 represent superior identification quality).

2.3 Drug Susceptibility Test

The E9 strain was isolated and cultured under standard laboratory conditions. Cultures were maintained on MRS agar plates and incubated at 37 °C for 24 hours. For liquid cultures, E9 was grown in nutrient broth (Haibo Biotechnology Co., Ltd., Qingdao, China) with shaking at 200 rpm at 37 °C. A panel of antimicrobial agents was selected for testing, including: Penicillin (PEN), Ampicillin (AM), Meropenem (MP), Vancomycin (VA), Erythromycin (EM), Clindamycin (CM), Linezolid (LZ). These antibiotics were all purchased from Sangon Biotech (Shanghai) Co., Ltd. (Shanghai, China). Stock solutions of these antibiotics were prepared according to the manufacturer's instructions and stored at -20 °C until use.

Antibiotic susceptibility profiles were assessed using the standardized Kirby-Bauer disk diffusion method (KB method). Strains were categorized as either susceptible (S) or resistant (R) based on inhibition zone measurements. Interpretation adhered to National Committee for Clinical Laboratory Standards (NCCLS) guidelines for non-fastidious bacteria, whereby bacterial sensitivity correlates directly with the diameter of the growth inhibition zone surrounding each antibiotic disk. Specifically, larger zones indicate greater susceptibility. Interpretive criteria varied for different antibiotic-impregnated disks (BioMérieux, France), as zone diameter thresholds defining susceptibility differ between antimicrobial agents.

A single colony of E9 was picked from the nutrient agar plate and inoculated into 5 mL of nutrient broth. The culture was incubated overnight at 37 °C with shaking. The overnight culture was then diluted to an optical density (OD) of 0.1 at 600 nm, corresponding to approximately 1×10^8 CFU/mL. After incubation, the diameter of the inhibition zones around each disk was measured using a ruler [11]. The inhibition zone diameters were recorded and analyzed. The susceptibility patterns of E9 were compared to the standard interpretive criteria to determine the efficacy of each antimicrobial agent. Statistical significance of observed differences was evaluated using GraphPad Prism 9.0 (Dotmatics, Boston, MA, USA) with $p < 0.05$ considered significant.

2.4 Metabolites Analysis

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Conditions: Chromatographic separation employed an ACE Excel2C-18PFP analytical column (100 × 2.1 mm, 2 μm; Aberdeen, Scotland) protected by a C18 guard column. The mobile phase comprised: (A) 0.1% formic acid in water and (B) 0.1% formic acid in acetonitrile. A gradient program was executed: initial hold at 2% B (1 min), linear ramp to 98% B over 10 min, isocratic hold at 98% B (2 min), rapid reduction to 2% B within 0.5 min, followed by column re-equilibration at 2% B (3 min). Operating parameters included: injection volume (2 μL), column temperature (35 °C), and duplicate sample injections.

Mass spectrometric detection utilized Heated Electrospray Ionization (HESI) under optimized conditions: spray voltage (3.5 kV), capillary temperature (300 °C), sheath gas flow (50 arb), auxiliary gas flow (10 arb), S-lens RF level (40), and S-lens voltage (25 V). Full scans were acquired at 70,000 resolution, with MS/MS spectra collected at 17,500 resolution.

Data Processing & Metabolite Identification: Raw data files (.d) were converted to .abf format using Abf-Converter. Subsequent data processing—including peak detection, alignment, and annotation—was performed in MS-DIAL (v4.90). Compound identification leveraged MS¹/MS² spectral matching against public repositories (MASSBANK, METLIN).

Peak Filtering & Quantification: Low-quality features (detection frequency <50% in QC and overall samples) were excluded. For redundant peaks assigned to identical compounds, only the highest-confidence annotation was retained. Remaining unannotated peaks were categorized as “unknowns” and included in global substance profiling for initial classification.

Peak stability was assessed via QC sample coefficient of variation (CV = RSD). Features with CV >30% were removed. Stable metabolites (annotated compounds with signal intensity ≥5 × blank) were selected for relative quantification. These filtered metabolite profiles were normalized using MetaboAnalystR (version 3.2, <https://github.com/xia-lab/MetaboAnalystR>) prior to statistical analysis.

2.5 *Lactobacillus reuteri* E9 Effects on Zebrafish Anxiety Model

Adult zebrafish were maintained in a controlled environment with a 14/10 hour light/dark cycle and fed twice daily. Anxiety was induced by exposing zebrafish to a 7.5 mM solution of pentylenetetrazol (PTZ) (Aladdin, Shanghai, China) for 20 minutes. Zebrafish were treated with E9 by adding the bacterial culture supernatant to the tank water at a final concentration of 1% (v/v) for 1 hour before PTZ exposure. After PTZ exposure, zebrafish behavior was recorded for 5 mins using a video tracking system. Key parameters included time spent in the top half of the tank, distance traveled, and freezing behavior. Zebrafish were

stained with a neural activity marker (e.g., c-Fos) and imaged using a fluorescent microscope (Minghui NIB950-FL, Guangzhou, China) to assess neural activity. The definition and quantification of areas based on Green fluorescent protein-Calmodulin-M13 Peptide (GCaMP) signal correlation with neuronal activity, or areas exhibiting enhanced calcium signaling, can be found in previously reported literature [12].

Experimental equipment utilized in zebrafish studies including Intelligent Breeding Management Suite (ZIBS), Microfluidics AutoLoader System (ZMFAL-100), Behavioral Imaging Analysis System (BH-100), Physiological Imaging Analysis System (PY-100) and Neuroimaging Analysis System (NS-100). All equipment was obtained from Guangdong Longseek Test Co., Ltd. (Guangzhou, China).

2.6 Behavioral Analysis of the Effect of GABA Receptor Antagonist NCS-382 on the Anxiolytic Activity of E9 in Zebrafish With PTZ-Induced Anxiety

Normally developed 5 dpf AB zebrafish were randomly selected and placed in a 6-well cell plate. The experiment included the following groups (24 zebrafish per group): control group, model group (PTZ), positive group (GABA), GABA+NCS-382 group, E9 group, and E9+NCS-382 group. The control and model groups were treated with E3 water, while the positive group received 500 μM GABA solution. The GABA+NCS-382 group was administered a mixture of 500 μM GABA and 10 μM NCS-382. The E9 group was treated with 1 × 10⁶ CFU/mL E9. The E9+NCS-382 group received a combination of 1 × 10⁶ CFU/mL *L. reuteri* E9 and 10 μM NCS-382, with 5 mL of solution per well. After daily incubation in a 28 °C biochemical incubator for 22 h, the solutions of the model group, positive group (GABA), GABA+NCS-382 group, E9 group, and E9+NCS-382 group were replaced with 7.5 mM PTZ solution for an additional 2-hour incubation. Fresh solutions were changed daily for 14 days. Subsequently, the plates were placed into a DanioVision zebrafish behavioral tracking system (Noldus), and the swimming behavior of larvae was recorded for 5 min under dark conditions. In pre-experiments, three velocity ranges were defined: static (0–4 mm/s), active (4–20 mm/s), and manic (>20 mm/s).

2.7 *Lactobacillus reuteri* E9 Effects on GABA and *Mtnrla* mRNA Expression

Zebrafish Maintenance: Adult zebrafish were housed under standard laboratory conditions with a 14/10 hour light/dark cycle. Zebrafish were treated with GABA (positive group, 500 μM) or E9 with different concentration (1 × 10⁴–10⁶ CFU/mL) by adding the bacterial culture supernatant to the tank water at a final concentration of 1% (v/v) for 1 hour daily for 7 days. Zebrafish larvae were anesthetized in a tricaine solution (0.1 g/L) and subsequently

Table 1. Antimicrobial susceptibility profile of *Lactobacillus reuteri* E9.

Antibacterial drug	Minimum Inhibitory Concentration (µg/mL)	Drug sensitivity
Penicillin (PEN)	1.5	Sensitiveness
Ampicillin (AM)	0.38	Sensitiveness
Meropenem (MP)	0.047	Sensitiveness
Vancomycin (VA)	≥256	Resistance
Erythromycin (EM)	0.25	Sensitiveness
Clindamycin (CM)	0.047	Sensitiveness
Linezolid (LZ)	1.0	Sensitiveness

ethanized by immersion in ice-cold E3 water bath as previously described [13,14]. Following treatment, zebrafish brains were dissected and snap-frozen in liquid nitrogen. Total RNA was isolated using TRIzol reagent (Vazyme, China) per manufacturer's protocol. cDNA was subsequently synthesized via reverse transcription of RNA employing a Hiscript III RT SuperMix kit (Vazyme, China). qPCR: Quantitative PCR (ChamQ Universal SYBR qPCR Master Mix, Vazyme, Nanjing, China) was performed using specific primers for GABA (primer F: TCAGGCA-GAGCTGGAAGGAT, primer R: TGCCGTTGTGGAA-GAACGT) and Melatonin Receptor 1a (Mtnrla, primer F: CTGGTGATTTTCTCCGTCTACAGA, primer R: CCGC-CACTGCCAAACTC). β -actin was used as the internal control, and the data were normalized to the expression of β -actin (primer F: GGTACCCATCTCCTGCTCCAA, primer R: GAGCGTGGCTACTCCTTACC). All DNA sequences used in this study were ordered from Sangon Biotechnology. Relative gene expression was calculated using the Delta-Delta-Ct ($\Delta\Delta Ct$) algorithm.

2.8 Statistic Analysis

All data analyses were conducted in SPSS 25.0 (IBM Corp., Chicago, IL, USA). Results are presented as means $\pm$ SEM. Survival and hatching rates were assessed via χ^2 test, while gene expression differences were evaluated using one-way ANOVA. Statistical significance was set at $p < 0.05$.

3. Results

3.1 DNA Sequencing, Physiological and Biochemical Characteristics and Antimicrobial Susceptibility Test of E9

Lactobacillus reuteri E9, isolated from traditional Anhui pickles, was cultured on MRS agar under anaerobic conditions at 37 °C. Colonies appeared white, spherical, smooth-surfaced, and entire-margined (**Supplementary Fig. 1**). 16S rRNA gene sequencing revealed 99.72% homology with *Limosilactobacillus reuteri* JCM 1112T (AP007281), with phylogenetic analysis presented in **Supplementary Fig. 2**.

Biochemical characterization of E9 revealed the production of D-galactose, sucrose, maltose, D-ribose, D-glucose, arginine, D-maltose, and L-arabinose following fermentation (**Supplementary Table 1**). Concurrently,

enzyme activity assays detected alanine-phenylalanine-proline arylamidase, urease, leucine arylamidase, β -galactosidase, β -D-fucosidase, phenylalanine arylamidase, tyrosine arylamidase, and α -arabinosidase.

Antimicrobial susceptibility testing of E9 revealed sensitivity to penicillin (PEN), ampicillin (AM), meropenem (MP), erythromycin (EM), clindamycin (CM), and linezolid (LZ), but resistance to vancomycin (VA) (**Table 1; Supplementary Fig. 3**). These findings support the potential of E9 for further development and utilization.

3.2 Metabolites of Zebrafish

Zebrafish were administered E9 for 7, 14, or 21 days commencing at 3 days post-fertilization (dpf), and neurotransmitter levels were quantified [15,16]. The entire fish was homogenized and processed to obtain samples for untargeted metabolomic analysis [17]. Compared to the control group, concentrations of the inhibitory neurotransmitters GABA, taurine, glycine, and serine were significantly elevated ($p < 0.05$) at 14 and 21 days post-intervention (**Fig. 1**). Notably, GABA and taurine levels in the E9-treated group increased twofold relative to controls after 14 days. These metabolites have been reported to exert sedative, anti-anxiety, and anticonvulsant effects, suggesting that E9 may improve sleep regulation [18,19].

3.3 Effects of *Lactobacillus reuteri* E9 on Zebrafish Behaviour

In this experiment, zebrafish were immobilized in a small microfluidic chip, allowing them to survive while maintaining a certain degree of mobility [20]. A microscope was focused on a single zebrafish to continuously capture images, which were then processed and superimposed by a computer to generate the heatmap. The color gradient from blue to red indicates an increasing number of superimposed images, reflecting higher zebrafish activity. By quantifying the tail swing speed and amplitude of the zebrafish, Average tail velocity and average range of motion angle were obtained, respectively. Figures illustrate the tail swing speed and amplitude in the control group, model group, positive control group (GABA), and three experimental groups treated with different concentrations of E9.

As shown in **Fig. 2A**, the green and red areas represent the tail movement trajectory coverage for zebrafish. Com-




Fig. 1. Effects of *Lactobacillus reuteri* E9 on inhibitory neurotransmitter levels in zebrafish. (A) γ -Aminobutyric acid (GABA), (B) 5-hydroxytryptamine (5-HT), (C) Taurine, (D) Glycine, and (E) Serine levels in zebrafish after 7, 14, and 21 days of E9 treatment. Data are presented as mean $\pm$ SEM ($n = 10$ per group). Experimental group was treated with E9 at 10^6 CFU/mL versus control group. ns denotes no significant difference and * represents $p < 0.05$, **: $p < 0.01$.

pared to the normal group, zebrafish in the PTZ-induced model group exhibited a significantly larger tail movement area, indicating increased locomotor activity. Concurrently, the model group showed significantly elevated tail movement angular velocity and amplitude ($p < 0.05$) compared to the normal group (Fig. 2B,C), confirming successful establishment of the insomnia model. Compared to the model group, zebrafish treated with GABA (positive control) displayed a reduced tail movement area (Fig. 2A), demonstrating that GABA attenuates locomotor activity in the PTZ-induced insomnia model. Furthermore, GABA treatment significantly decreased tail movement angular velocity and amplitude relative to the model group ($p < 0.05$; Fig. 2B,C).

Similar to GABA, zebrafish treated with E9 exhibited a reduced tail movement area compared to the model group (Fig. 2A), indicating attenuated locomotor activity in the PTZ-induced insomnia model. Furthermore, E9 administration significantly decreased tail movement angular velocity and amplitude relative to the model group ($p < 0.05$; Fig. 2B,C). These effects are consistent with sedative-hypnotic properties, demonstrating that E9 produces a similar behavioral response to GABA. Additionally, an experimentally recorded video visually illustrating the effects of E9 is provided in the **Supplementary Information**.

3.4 Effects of *Lactobacillus reuteri* E9 on Brain Discharge in Zebrafish

Tg(Elavl3:H2B-GCaMP6f) zebrafish were utilized to assess the effects of E9 on neuronal activity [21,22]. Lin *et al.* [12] present an *in vivo* drug screening platform integrating high-throughput brain-wide activity mapping with machine learning-based predictive analytics. This approach leverages calcium-sensitive fluorophore fluorescence as a well-established neuronal activity indicator. To enable large-scale investigation of central nervous system (CNS) physiology, the team engineered an autonomous system for parallel imaging of awake, non-anesthetized zebrafish larvae. The system utilizes a hydrodynamically operated microfluidic chip capable of trapping, positioning, and orienting multiple larvae simultaneously for brain-wide neuronal recordings [12].

Fig. 3 depicts brain regions exhibiting baseline (blue) and elevated (yellow) fluorescence, representing neuronal discharge. Compared to the normal group, PTZ-exposed zebrafish showed significantly increased neuronal activation area, confirming PTZ-induced CNS excitation. The GABA treatment group exhibited markedly reduced activation area versus the model group, demonstrating GABA's inhibition of PTZ-induced neuronal discharge and its




Fig. 2. Behavioral analysis of PTZ-induced anxiety in zebrafish treated with *Lactobacillus reuteri* E9. (A) Representative tail movement trajectories. (B) Average tail swing angular velocity and (C) average tail swing angle of zebrafish in control, PTZ-induced model, GABA-treated, and E9-treated groups. Data are mean $\pm$ SEM ($n = 15$ per group). ## indicates a significant difference between the normal and model groups ($p < 0.01$). * indicates a comparison between the sample group and the model group, with * representing $p < 0.05$, and ** representing $p < 0.01$. GABA-treated as positive control (500 μ M). PTZ (7.5 mM, 20 min) induced hyperactivity, while E9 (1% v/v, 1 h pre-treatment) reversed these effects. Behavioral tracking was performed using EthoVision XT software (Noldus).

sedative-hypnotic effect. Similarly, E9 administration significantly suppressed PTZ-induced neuronal activation area relative to the model group. This indicates that E9 attenuates pathological neuronal discharge, consistent with sedative-hypnotic activity.

3.5 Effects of *Lactobacillus reuteri* E9 on the Expression of GABA and Mtnrlaa Gene in Zebrafish

Analysis of sleep-related pathway gene expression provides RNA-level assessment of sedative-hypnotic efficacy [23–25]. As shown in Fig. 4: PTZ-exposed zebrafish exhibited significantly downregulated expression of the GABA receptor gene and melatonin receptor gene (Mtnrlaa) versus the normal group ($p < 0.05$). GABA-treated fish showed significant upregulation of GABA receptor gene and Mtnrlaa expression compared to the PTZ model group ($p < 0.001$). E9 administration similarly in-

creased expression of both genes relative to the PTZ group ($p < 0.05$). These results demonstrate that E9 upregulates key sleep-regulatory genes (GABA receptor gene and Mtnrlaa) in zebrafish, paralleling GABA's transcriptional effects.

3.6 The Inhibitory Effect of the GABA Receptor Antagonist NCS-382 on the Effect of *Lactobacillus reuteri* E9 in Alleviating PTZ-Induced Anxiety in Zebrafish

As shown in Fig. 5. Compared with the model group, both GABA and E9 significantly reduced the total swimming distance and average swimming speed of zebrafish ($p < 0.001$). Additionally, GABA and E9 significantly decreased the manic time and active time of zebrafish ($p < 0.001$), while significantly increasing their static time ($p < 0.001$). However, the application of the GABA receptor antagonist NCS-382 antagonized the above effects of GABA




Fig. 3. *Lactobacillus reuteri* E9 suppresses PTZ-induced neuronal hyperactivity in zebrafish brains. Zebrafish in (A) normal (control group), (B) PTZ-induced model (model group), (C) GABA-treated (positive group), and E9-treated with different concentrations (experiment groups): (D) 1×10^4 CFU/mL, (E) 1×10^5 CFU/mL and (F) 1×10^6 CFU/mL. The left part show fluorescence images of brain activity in Tg(Elavl3:H2B-GCaMP6f) zebrafish (blue: baseline activity; yellow: PTZ-induced hyperactivity). The right part present quantification of brain discharge area (normalized to control). Data are mean $\pm$ SEM ($n = 8$ per group). E9 treatment (1% v/v, 7 days) significantly reduced PTZ-induced neuronal excitation. Imaging parameters: 20 $\times$ objective, 488 nm excitation.

and E9. These findings suggest that E9 may alleviate PTZ-induced anxiety in zebrafish by metabolizing GABA.

4. Discussion

The E9 strain demonstrated superior antimicrobial susceptibility profiles, indicating robust potential against diverse pathogens. This high efficacy likely stems from strain-specific bioactive metabolites that require further isolation and characterization [26,27]. Probiotic has signifi-

cant pathogen-inhibiting capacity positions it as a promising candidate for augmenting antimicrobial strategies amid rising antibiotic resistance. In PTZ-induced zebrafish anxiety models, E9 significantly ameliorated anxiety-like behaviors, as evidenced by improved behavioral trajectories and reduced neurological hyperactivity. These findings strongly suggest E9 confers neurologically mediated anxiolytic effects, supporting its therapeutic potential for anxiety disorders.




Fig. 4. *Lactobacillus reuteri* E9 upregulates GABA and melatonin receptor gene expression in zebrafish. Relative mRNA levels of (A) GABA receptor and (B) melatonin receptor 1aa (Mtnr1aa) in zebrafish brains. Data are normalized to β -actin and presented as fold change (mean $\pm$ SEM, n = 12 per group). # indicates a comparison between the normal group and the model group with # representing $p < 0.05$, * indicates a comparison between the sample group and the model group, with * representing $p < 0.05$, ** representing $p < 0.01$, and *** representing $p < 0.001$. Gene expression analysis was performed via qPCR.




Fig. 5. Behavioral analysis of the inhibitory effect of GABA receptor antagonist NCS-382 on the anxiolytic activity of E9 in zebrafish with PTZ-induced anxiety. (A) Total swimming distance. (B) Average swimming speed. (C) Mania time. (D) Activity time. (E) Static time(s). Data are presented as mean $\pm$ SEM (n = 24/group). ** $p < 0.01$; *** $p < 0.001$. Behavioral tracking was performed using EthoVision XT software (Noldus).

Zebrafish were selected as the model organism based on their high genetic homology to humans and well-documented utility in neurobehavioral research [28,29]. The observed anxiolytic effects demonstrate translational relevance for developing novel human anxiety therapeutics, though validation in mammalian models and subsequent clinical trials remains essential [30]. qPCR analysis elucidated molecular mechanisms underlying probiotic efficacy against severe insomnia, revealing modulation of sleep- and anxiety-regulatory gene networks. These findings indicate E9 likely mediates its effects through pathways governing neurotransmitter dynamics, receptor sensitization, and neuroinflammatory processes.

The specific genes and pathways identified represent promising targets for elucidating probiotic therapeutic mechanisms. And defining precise molecular interactions will be essential for developing targeted therapies leveraging probiotic benefits [31,32]. Further characterization of E9 metabolite-pathway crosstalk may yield novel therapeutic compounds. While current findings are promising, key areas require investigation: Isolation and characterization of probiotic bioactive components responsible for antimicrobial/anxiolytic effects to enable standardized formulation development. Besides, long-term safety and efficacy assessment for chronic administration, including potential side effects and drug interactions. What's more, Validation in mammalian models to advance toward clinical translation and exploration of therapeutic potential for other neuropsychiatric conditions (e.g., depression, PTSD, neurodegenerative diseases) given probiotic neuromodulatory properties [33,34].

In summary, E9 holds considerable promise as a dual-function agent for antimicrobial interventions and anxiety behavior modulation. The integrated mechanistic and behavioral evidence presented establishes a robust foundation for translational development. Through continued elucidation of its mode of action and expanded therapeutic exploration, E9 emerges as a compelling candidate for addressing both infectious disease challenges and neuropsychiatric disorders.

5. Conclusion

In summary, *Lactobacillus reuteri* E9 demonstrates dual therapeutic potential as both an antimicrobial agent and a neuromodulator for sleep disorders. Our findings establish that E9 produces inhibitory neurotransmitters (GABA, glycine, serine, taurine) and upregulates GABA/Mtnrlaa receptor expression in zebrafish, reversing PTZ-induced insomnia. It significantly suppresses neuronal hyperactivity and ameliorates anxiety-like behaviors in PTZ model. The strain exhibits broad-spectrum antibiotic susceptibility with intrinsic bioactive metabolites. These results validate E9's mechanistic role in GABA pathway modulation via the microbiota-gut-brain axis, positioning it as a promising non-pharmaceutical intervention for sleep disorders. Future

work should isolate active metabolites, validate efficacy in mammalian models, and explore clinical translation.

Availability of Data and Materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Author Contributions

Conceptualization, YJ, WZ; methodology, YJ, LG, and YL; validation, WZ; investigation, YJ, LG, HH, HC, TC, YL; resources, WZ; data curation, HH, HC and TC; writing—preparation of the original project, YJ, YL; writing—reviewing and editing, LG, YL and WZ; visualization, YL; supervision, YL, WZ. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

Ethics Approval and Consent to Participate

All zebrafish procedures followed the 3R principles (Replacement, Reduction, Refinement) and complied with GB/T 35892-2018 ethical guidelines, under approval from the Laboratory Animal Welfare and Ethics Committee. All zebrafish experiments were approved and met the ethical standards of the Institutional Review Board of the Laboratory Animal Ethics Committee, Center of Human Microecology Engineering and Technology of Guangdong Province (approval number: IACUC MC 0925-01-2024).

Acknowledgment

We thank Zhao Zhang and Kangdi Zheng (Center of Human Microecology Engineering and Technology of Guangdong Province, Guangdong Longsee Biomedical Corporation, Guangzhou, China) for statistical consultation and technical support provided by the Longseek high-throughput zebrafish screening platform for drug and probiotic evaluation. Also we acknowledge Dr. Chongxi Yang from La Trobe University (Australia) for language polishing.

Funding

This study was funded by 2023 Chizhou City major science and technology special project.

Conflict of Interest

The authors declare no conflict of interest.

Supplementary Material

Supplementary material associated with this article can be found, in the online version, at <https://doi.org/10.31083/FBL39587>.

References

- [1] Gottesman RF, Lutsey PL, Benveniste H, Brown DL, Full KM, Lee JM, *et al.* Impact of Sleep Disorders and Disturbed Sleep on Brain Health: A Scientific Statement From the American Heart Association. *Stroke*. 2024; 55: e61–e76. <https://doi.org/10.1161/STR.0000000000000453>.
- [2] Dauvilliers Y. Future drugs for sleep and wake disorders. *Bulletin de l'Académie Nationale de Médecine*. 2020; 204: 1047–1052. <https://doi.org/10.1016/j.banm.2020.09.027>.
- [3] Yang DF, Huang WC, Wu CW, Huang CY, Yang YCSH, Tung YT. Acute sleep deprivation exacerbates systemic inflammation and psychiatry disorders through gut microbiota dysbiosis and disruption of circadian rhythms. *Microbiological Research*. 2023; 268: 127292. <https://doi.org/10.1016/j.micres.2022.127292>.
- [4] Wang Z, Wang Z, Lu T, Chen W, Yan W, Yuan K, *et al.* The microbiota-gut-brain axis in sleep disorders. *Sleep Medicine Reviews*. 2022; 65: 101691. <https://doi.org/10.1016/j.smrv.2022.101691>.
- [5] Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, *et al.* Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nature Reviews. Gastroenterology & Hepatology*. 2014; 11: 506–514. <https://doi.org/10.1038/nrgastro.2014.66>.
- [6] Yu B, Wang KY, Wang NR, Zhang L, Zhang JP. Effect of probiotics and paraprobiotics on patients with sleep disorders and sub-healthy sleep conditions: a meta-analysis of randomized controlled trials. *Frontiers in Neurology*. 2024; 15: 1477533. <https://doi.org/10.3389/fneur.2024.1477533>.
- [7] Ito H, Tomura Y, Kitagawa Y, Nakashima T, Kobanawa S, Uki K, *et al.* Effects of probiotics on sleep parameters: A systematic review and meta-analysis. *Clinical Nutrition ESPEN*. 2024; 63: 623–630. <https://doi.org/10.1016/j.clnesp.2024.07.006>.
- [8] Du Q, Li Q, Liu C, Liao G, Li J, Yang J, *et al.* Probiotics/prebiotics/synbiotics and human neuropsychiatric outcomes: an umbrella review. *Beneficial Microbes*. 2024; 15: 589–608. <https://doi.org/10.1163/18762891-bja00035>.
- [9] Tette FM, Kwofie SK, Wilson MD. Therapeutic Anti-Depressant Potential of Microbial GABA Produced by *Lactobacillus rhamnosus* Strains for GABAergic Signaling Restoration and Inhibition of Addiction-Induced HPA Axis Hyperactivity. *Current Issues in Molecular Biology*. 2022; 44: 1434–1451. <https://doi.org/10.3390/cimb44040096>.
- [10] Al Kassaa I, Hamze M, Hober D, Chihib NE, Drider D. Identification of vaginal lactobacilli with potential probiotic properties isolated from women in North Lebanon. *Microbial Ecology*. 2014; 67: 722–734. <https://doi.org/10.1007/s00248-014-0384-7>.
- [11] Chen T, Li B, Zheng K, Liu Y, Zhang Z, Hu H, *et al.* *Lactobacillus paracasei* R3 Alleviates Tumor Progression in Mice with Colorectal Cancer. *Current Microbiology*. 2023; 81: 38. <https://doi.org/10.1007/s00284-023-03525-4>.
- [12] Lin X, Duan X, Jacobs C, Ullmann J, Chan CY, Chen S, *et al.* High-throughput brain activity mapping and machine learning as a foundation for systems neuropharmacology. *Nature Communications*. 2018; 9: 5142. <https://doi.org/10.1038/s41467-018-07289-5>.
- [13] Chen Y, Zheng K, Leng Y, Zhang Z, Li X, Li X, *et al.* Alleviating effect of *Lactobacillus fermentum* E15 on hyperlipidemia and hepatic lipid metabolism in zebrafish fed by a high-fat diet through the production of short-chain fatty acids. *Frontiers in Nutrition*. 2025; 12: 1522982. <https://doi.org/10.3389/fnut.2025.1522982>.
- [14] Liu D, Yu H, Pang Q, Zhang X. Investigation of the Lipid-Lowering Effect of Vitamin C Through GSK-3 β / β -Catenin Signaling in Zebrafish. *Frontiers in Physiology*. 2018; 9: 1023. <https://doi.org/10.3389/fphys.2018.01023>.
- [15] Torres-Hernández BA, Del Valle-Mojica LM, Ortiz JG. Valerianic acid and Valeriana officinalis extracts delay onset of Pentylentetrazole (PTZ)-Induced seizures in adult Danio rerio (Zebrafish). *BMC Complementary and Alternative Medicine*. 2015; 15: 228. <https://doi.org/10.1186/s12906-015-0731-3>.
- [16] Ravikumar M, Durairaj B, Uvarajan D. Necrostatin-1 as a Potential Anticonvulsant: Insights from Zebrafish Larvae Model of PTZ-Induced Seizures. *Molecular Neurobiology*. 2025; 62: 4534–4544. <https://doi.org/10.1007/s12035-024-04571-0>.
- [17] Liu R, Guo Y, Yu J, Wei X, Zhou F, Yuan X, *et al.* Protective effect of N-(E)-p-coumaroyltyrosine on LPS-induced acute inflammatory injury and signaling pathway analysis. *Fish & Shellfish Immunology*. 2024; 144: 109242. <https://doi.org/10.1016/j.fsi.2023.109242>.
- [18] Wei Y, Xu J, Miao S, Wei K, Peng L, Wang Y, *et al.* Recent advances in the utilization of tea active ingredients to regulate sleep through neuroendocrine pathway, immune system and intestinal microbiota. *Critical Reviews in Food Science and Nutrition*. 2023; 63: 7598–7626. <https://doi.org/10.1080/10408398.2022.2048291>.
- [19] Pimenta AI, Bernardino RM, Pereira IAC. Role of sulfidogenic members of the gut microbiota in human disease. *Advances in Microbial Physiology*. 2024; 85: 145–200. <https://doi.org/10.1016/bs.ampbs.2024.04.003>.
- [20] Lin X, Wang S, Yu X, Liu Z, Wang F, Li WT, *et al.* High-throughput mapping of brain-wide activity in awake and drug-responsive vertebrates. *Lab on a Chip*. 2015; 15: 680–689. <https://doi.org/10.1039/c4lc01186d>.
- [21] Freeman J, Vladimirov N, Kawashima T, Mu Y, Sofroniew NJ, Bennett DV, *et al.* Mapping brain activity at scale with cluster computing. *Nature Methods*. 2014; 11: 941–950. <https://doi.org/10.1038/nmeth.3041>.
- [22] Zhao S, Qian Y, Mu Y. Tracking single cells in zebrafish brain. *Journal of Neuroscience Methods*. 2021; 353: 109086. <https://doi.org/10.1016/j.jneumeth.2021.109086>.
- [23] Zhang H, Gao T, Zhao F, Wang N, Li Z, Qin X, *et al.* Integrated gut microbiome and metabolomic analyses elucidate the therapeutic mechanisms of Suanzaoren decoction in insomnia and depression models. *Frontiers in Neuroscience*. 2024; 18: 1459141. <https://doi.org/10.3389/fnins.2024.1459141>.
- [24] Cheng J, Wu Q, Sun R, Li W, Wang Z, Zhou M, *et al.* Protective effects of a probiotic-fermented germinated grain complex on neurotransmitters and sleep quality in sleep-deprived mice. *Frontiers in Microbiology*. 2024; 15: 1438928. <https://doi.org/10.3389/fmicb.2024.1438928>.
- [25] Li YS, Cui GZ, Su DL, Song L. Assessment of the Sleep-Improving Efficacy of Yak Milk Powder Based on a Zebrafish Insomnia Model. *Food Industry*. 2024; 8: 78–82. (In Chinese)
- [26] Huang J, Yang Z, Li Y, Chai X, Liang Y, Lin B, *et al.* *Lactobacillus paracasei* R3 protects against dextran sulfate sodium (DSS)-induced colitis in mice via regulating Th17/Treg cell balance. *Journal of Translational Medicine*. 2021; 19: 356. <https://doi.org/10.1186/s12967-021-02943-x>.
- [27] Song W, Liu J, Yang J, Chen T, Zhu J, Liu X. Colonizable probiotic *Lactobacillus paracasei* R3 enhances ICI therapy via modulating PBMCs differentiation. *Frontiers in Microbiology*. 2025; 16: 1547964. <https://doi.org/10.3389/fmicb.2025.1547964>.
- [28] Vaz RL, Outeiro TF, Ferreira JJ. Zebrafish as an Animal Model for Drug Discovery in Parkinson's Disease and Other Movement Disorders: A Systematic Review. *Frontiers in Neurology*. 2018; 9: 347. <https://doi.org/10.3389/fneur.2018.00347>.
- [29] Choi TY, Choi TI, Lee YR, Choe SK, Kim CH. Zebrafish as an animal model for biomedical research. *Experimental & Molecular Medicine*. 2021; 53: 310–317. <https://doi.org/10.1038/s41598-021-00310-0>.

1038/s12276-021-00571-5.

- [30] Tian C, Deng S, Zhang Z, Zheng K, Wei L. Bifidobacterium bifidum 1007478 derived indole-3-lactic acid alleviates NASH via an aromatic hydrocarbon receptor-dependent pathway in zebrafish. *Life Sciences*. 2025; 369: 123557. <https://doi.org/10.1016/j.lfs.2025.123557>.
- [31] Gao Q, Fan T, Luo S, Zheng J, Zhang L, Cao L, *et al*. Lactobacillus gasseri LGV03 isolated from the cervico-vagina of HPV-cleared women modulates epithelial innate immune responses and suppresses the growth of HPV-positive human cervical cancer cells. *Translational Oncology*. 2023; 35: 101714. <https://doi.org/10.1016/j.tranon.2023.101714>.
- [32] Zhang Z, Zheng K, Zhang Z, Cao L, Lin L, Sun W, *et al*. Lactobacillus gasseri LGV03-derived indole-3-lactic acid ameliorates immune response by activating aryl hydrocarbon receptor. *Microbial Cell Factories*. 2025; 24: 34. <https://doi.org/10.1186/s12934-025-02662-8>.
- [33] Liu S, Men X, Guo Y, Cai W, Wu R, Gao R, *et al*. Gut microbes exacerbate systemic inflammation and behavior disorders in neurologic disease CADASIL. *Microbiome*. 2023; 11: 202. <https://doi.org/10.1186/s40168-023-01638-3>.
- [34] Yu Y, Zhu J, Fu R, Guo L, Chen T, Xu Z, *et al*. Unique intestinal microflora and metabolic profile in different stages of hypertension reveal potential biomarkers for early diagnosis and prognosis. *Journal of Medical Microbiology*. 2024; 73. <https://doi.org/10.1099/jmm.0.001839>.